Editorial Board — Medscape Oncology
Board Members
- Harold J. Burstein, MD, PhD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- Bruce D. Cheson, MD
- Georgetown University
Georgetown University Hospital
Washington, DC
- Georgetown University
- Avraham Eisbruch, MD
- University of Michigan
University of Michigan Hospital
Ann Arbor, Michigan
- University of Michigan
- David J. Kerr, MD
- University of Oxford
Oxford Cancer Centre
Oxford, United Kingdom
- University of Oxford
- Mark G. Kris, MD
- Memorial Sloan-Kettering Cancer Center
Weill Cornell Medical College
New York, New York
- Memorial Sloan-Kettering Cancer Center
- Corey J. Langer, MD
- University of Pennsylvania Medical School
Abramson Cancer Center
Philadelphia, Pennsylvania
- University of Pennsylvania Medical School
- Maurie Markman, MD
- Drexel University College of Medicine
Cancer Treatment Centers of America
Philadelphia, Pennsylvania
- Drexel University College of Medicine
- John L. Marshall, MD
- Georgetown University
Washington, DC
- Georgetown University
- Kathy D. Miller, MD
- Indiana University School of Medicine
Indiana University Simon Cancer Center
Indianapolis, Indiana
- Indiana University School of Medicine
- Richard M. Stone, MD
- Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
- Harvard Medical School
- Nicholas J. Vogelzang, MD
- University of Nevada School of Medicine
US Oncology Research
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
- University of Nevada School of Medicine
- Louis M. Weiner, MD
- Georgetown University
Georgetown University Medical Center
Washington, DC
- Georgetown University
- John R. Wingard, MD
- University of Florida
Shands Cancer Hospital at the University of Florida
Gainesville, Florida
- University of Florida
Board Member Details
Harold J. Burstein, MD, PhD
Associate Professor of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute, Boston, Massachusetts
Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.
Bruce D. Cheson, MD
Professor of Medicine, Department of Hematology-Oncology; Deputy Chief, Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC
Bruce D. Cheson, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celgene; Astellas; Pharmacyclics; Gilead; Roche-Genentech; AbbVie
Avraham Eisbruch, MD
Professor, University of Michigan; Associate Chair, University of Michigan Hospital, Ann Arbor, Michigan
Avraham Eisbruch, MD, has disclosed the following relevant financial relationships:
Received research grant from: National Institutes of Health (RO1)
David J. Kerr, CBE, MD, DSc, FRCP, FMedSci
Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom
David Kerr, CBE, MD, DSc, FRCP, FMedSci, has disclosed the following relevant financial relationships:
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Oxford Cancer Biomarkers; OxOnc; Celleron Therapeutics Ltd; Cancer Care Commission
Serve(d) as a speaker or a member of a speakers bureau for: Merck-Serono
Received research grant from: Roche; Bayer
Have a 5% or greater equity interest in: Oxford Cancer Biomarkers; Celleron Therapeutics Ltd; Cancer Care Commission
Received income in an amount equal to or greater than $250 from: Oxford Cancer Biomarkers; OxOnc; Celleron Therapeutics
Mark G. Kris, MD
Professor of Medicine, Weill Cornell Medical College; Attending Physician, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
Mark G. Kris, MD, has disclosed no relevant financial relationships.
Corey J. Langer, MD
Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania
Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Bristol-Myers Squibb Company; Pfizer Inc; Eli Lilly and Company; Genentech, Inc.; OSI Pharmaceuticals, Inc.; Merck & Co. Inc; GlaxoSmithKline; Nektar; Clovis Oncology
Served as a scientific advisor for: Bristol-Myers Squibb Company; ImClone Systems Incorporated; sanofi-aventis; Pfizer Inc; Eli Lilly and Company; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Genentech, Inc.; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Abbott Laboratories; Morphobiotek, Inc.; Biodesix; Clariant; CarisDx; Vertex; Synta Pharmaceuticals Corp.; Celegene; Boehringer Ingelheim Pharmaceuticals, Inc.; AbbVie; Clovis Oncology; Merck & Co. Inc
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; OSI Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ImClone Systems Incorporated (all curtailed as of 12/10)
Data Safety Monitoring Committee Member: Eli Lilly and Company; Amgen Inc; Synta Pharmaceuticals Corp.; Agennix; Peregrine; SWOG; Incyte Corporation
CME: Imedex; Physicians Education Resource; TRM Oncology
Maurie Markman, MD
Clinical Professor, Drexel University College of Medicine; President, Medical & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania
Maurie Markman, MD, has disclosed the following relevant financial relationships:
Received income in an amount equal to or greater than $250 from: Genentech, Inc; AstraZeneca Pharmaceuticals LP; Celgene; Clovis; Amgen
John L. Marshall, MD
Professor of Medicine; Chief, Division of Hematology-Oncology; Director, Clinical Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Taiho Oncology; Celgene Corporation; Caris Life Sciences
Serve(d) as a speaker or member of a speakers bureau for: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Taiho Oncology; Celgene Corporation; Caris Life Sciences
Received research grant from: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Taiho Oncology; Celgene Corporation; Caris Life Sciences
Kathy D. Miller, MD
Professor, Department of Medicine (Hematology-Oncology), Indiana University Simon Cancer Center; Co-Director, Breast Cancer Program, Indiana University Simon Cancer Center, Indianapolis, Indiana
Kathy D. Miller, MD, has disclosed no relevant financial relationships.
Richard M. Stone, MD
Professor of Medicine, Harvard Medical School; Director, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts
Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Received research grant from: Novartis Pharmaceuticals Corporation
Received income in an amount equal to or greater than $250 from: Amgen Inc; Abbvie; Roche; Seattle Genetics, Inc; Bristol-Myers Squibb Company; Celator
Nicholas J. Vogelzang, MD
Research Medical Director, US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Nicholas J. Vogelzang, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen Inc.; Janssen Biotech, Inc; BIND Biosciences; AVEO
Serve(d) as a speaker or a member of a speakers bureau for: Dendreon Corporation; Bayer HealthCare Pharmaceuticals; Medivation, Inc.; Caris Molecular Profiling Institute; Millennium Pharmaceuticals, Inc; sanofi-aventis; GlaxoSmithKline
Received honoraria from: DAVA Oncology; Mannkind; UpToDate; Abbvie; Bavarian Nordic; Endocyte
Stock: Caris Life Sciences
Received research funding from: PAREXEL International; Progenics Pharmaceuticals, Inc; Exelixis; US Oncology; Viamet Pharmaceuticals; Endocyte; GlaxoSmithKline
Received travel, accommodations, or expenses from: Genentech/Roche; Celgene; US Oncology; Dendreon; Novartis Pharmaceuticals Corporation; Pfizer Inc; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Exelixis
Louis M. Weiner, MD
Francis L. and Charlotte G. Gragani Chair and Professor, Department of Oncology, Georgetown University Medical Center; Clinical Director of Cancer Services, Georgetown University Hospital, Washington, DC
Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AbbVie Inc.; Genentech BioOncology; Merck & Co., Inc.; Mylan Laboratories Inc.; Novartis Pharmaceuticals
Serve(d) on the scientific advisory board for: Celldex Therapeutics, Inc.; Jounce Therapeutics, Inc.; Merrimack Pharmaceuticals, Inc.
Serve(d) on the external advisory board for: CytomX Therapeutics, Inc.
Investment in: Targeted Diagnostics & Therapeutics, Inc.
John R. Wingard, MD
Professor of Medicine, University of Florida; Director, Bone Marrow Transplant Program, Shands Hospital at the University of Florida Health, Gainesville, Florida
John R. Wingard, MD, has disclosed the following relevant financial relationships:
Serve(d) on the Board of Directors for: National Marrow Donor Program
Received consultant fees from: Astellas Pharma, Inc.; Merck & Co., Inc; Gilead Sciences, Inc.; Fate Therapeutics, Inc.; Shire; Ansun BioPharma